Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Status
- TERMINATED
- Phase
- PHASE2
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- Status
- RECRUITING
- Phase
- PHASE3